Understanding PML Risk with Tysabri: Who Should Be Monitored?
From General Health Awareness to Legal Action
If you or a loved one takes Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare brain infection has been documented in published reports and FDA labeling, and monitoring is recommended for certain patients. Building on decades of medical research, this page explains who may need monitoring and what the evidence shows.
Understanding Tysabri and Its Link to PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, resulting in demyelination and progressive neurological deterioration. Clinical presentation of PML typically includes subacute onset of focal neurological deficits such as weakness, gait disturbance, cognitive impairment, visual field defects, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The disease course is often rapid, leading to severe disability or death within months if untreated. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on lymphocytes, preventing their migration across the blood-brain barrier into the central nervous system. This immunosuppressive effect reduces immune surveillance in the brain, allowing latent JCV to replicate unchecked and cause lytic infection of oligodendrocytes. The boxed warning identifies three established risk factors for PML: presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment.
FDA Adverse Event Reports and Risk Context
FDA adverse event reports from the FAERS database list PML-related symptoms among the most frequently reported events for Tysabri, including fatigue (19,150 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the neurological burden observed in treated patients. The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations. The boxed warning explicitly states that Tysabri increases PML risk and mandates enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to ensure patients understand the risks and are monitored (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers and patients were adequately informed of the magnitude of risk, particularly in the context of duration of therapy and prior immunosuppressant use.
Statute of Limitations for Tysabri Claims in Washington
For affected patients in Washington, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, the timeline between exposure and documented harm is critical. PML typically develops after months to years of Tysabri treatment, with the boxed warning noting that duration of therapy is a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be gradual, and diagnosis can be delayed, complicating the determination of when the injury was discovered. Patients who develop PML should consult an attorney promptly to assess their legal options, as the statute of limitations may begin running from the date of diagnosis or when symptoms first became apparent. The risk narrative underscores the importance of timely legal action. Given the severe outcomes of PML—death or severe disability—affected individuals and their families may seek compensation for medical expenses, lost income, and pain and suffering. An attorney can evaluate whether the warnings provided were adequate and whether the prescribing physician adhered to the monitoring and risk mitigation protocols outlined in the TOUCH program. The evidence from the prescribing information and adverse event reports provides a factual basis for understanding the link between Tysabri and PML, the risk factors involved, and the clinical consequences.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Washington?
In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, this may begin from the date of diagnosis or when symptoms first became apparent. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable timeframe.
What are the risk factors for developing PML while taking Tysabri?
The boxed warning for Tysabri identifies three established risk factors for PML: presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when assessing individual risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.